Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current pharmaceutical design

• Publication date

  2012-12-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/138161213804143617PMID 22920907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

  2012cited by this paper
• Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

  2012cited by this paper
• Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.

  2012cited by this paper
• Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

  2011cited by this paper
• Biogen Idec restructures, sharpens neurology focus

  2011cited by this paper
• Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

  2011cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011cited by this paper
• A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

  2011cited by this paper
• The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

  2011cited by this paper
• Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer

  2011cited by this paper
• HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

  2011cited by this paper
• Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

  2011cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• HSP90 at the hub of protein homeostasis: emerging mechanistic insights

  2010cited by this paper
• New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

  2010cited by this paper
• Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

  2010cited by this paper
• Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90.

  2010cited by this paper
• STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.

  2010cited by this paper
• Targeting the dynamic HSP90 complex in cancer

  2010cited by this paper
• Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

  2009cited by this paper
• Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.

  2009cited by this paper
• Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

  2009cited by this paper
• Update on Hsp90 inhibitors in clinical trial.

  2009cited by this paper
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease

  2007cited by this paper
• Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

  2005cited by this paper
• Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.

  2005cited by this paper
• Synthesis and antitumor activity of novel O-carbamoylmethyloxime derivatives of radicicol.

  2003cited by this paper
• Development of radicicol analogues.

  2003cited by this paper
• Natural product origins of Hsp90 inhibitors.

  2003cited by this paper
• Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.

  2002cited by this paper
• Heat Shock Protein 90-antagonist Destabilizes Bcr-Abl/HSP90 Chaperone Complex

  2002cited by this paper
• Multiple myeloma

  2001cited by this paper
• A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.

  2001cited by this paper
• A Radicicol Derivative, KF58333, Inhibits Expression of Hypoxia‐inducible Factor‐1α and Vascular Endothelial Growth Factor, Angiogenesis and Growth of Human Breast Cancer Xenografts

  2001cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Stereospecific antitumor activity of radicicol oxime derivatives

  2001cited by this paper
• Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

  2000cited by this paper
• Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.

  2000cited by this paper
• Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.

  2000cited by this paper
• KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.

  1999cited by this paper
• Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin.

  1999cited by this paper
• Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol

  1998cited by this paper
• Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.

  1998cited by this paper
• Radicicol Leads to Selective Depletion of Raf Kinase and Disrupts K-Ras-activated Aberrant Signaling Pathway*

  1998cited by this paper
• Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.

  1994cited by this paper
• Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive

  1992cited by this paper
• Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.

  1992cited by this paper
• Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.

  1989cited by this paper

• Targeted protein degradation of HSP90 and associated proteins for cancer therapy via PROTACs and beyond.

  2025cites this paper
• Biotinylated Hsp90β-selective inhibitors.

  2025cites this paper
• In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy

  2025influential citation
• Combination Strategies with HSP90 Inhibitors in Cancer Therapy: Mechanisms, Challenges, and Future Perspectives

  2025cites this paper
• Prognosis value of heat-shock proteins in esophageal and esophagogastric cancer: A systematic review and meta-analysis

  2024cites this paper
• Role of TRAP1 Protein in the Development and Progression of Glioblastoma

  2024cites this paper
• Protective role of the HSP90 inhibitor, STA-9090, in lungs of SARS-CoV-2-infected Syrian golden hamsters

  2024cites this paper
• Therapeutic Potential of Heat Shock Protein 90 Inhibitors, Geldanamycin, and Analog Compounds in Precision Cancer Therapy

  2023influential citation
• Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center

  2023cites this paper
• A Drug Screening Reveals Minocycline Hydrochloride as a Therapeutic Option to Prevent Breast Cancer Cells Extravasation across the Blood–Brain Barrier

  2022cites this paper
• Molecular target interactions of quinoline derivatives as anticancer agents: A review

  2022influential citation
• HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)

  2022cites this paper
• The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

  2022cites this paper
• Tissue protective role of Ganetespib in SARS-CoV-2-infected Syrian golden hamsters

  2022cites this paper
• Complex Crystal Structure Determination and in vitro Anti–non–small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112

  2021cites this paper
• Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90

  2021cites this paper
• Recent advances in heat shock proteins in cancer diagnosis, prognosis, metabolism and treatment.

  2021cites this paper
• HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF)

  2020cites this paper
• Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

  2020cites this paper
• The Role of Heat Shock Protein -90 (HSP-90) in Inflammatory Disorders

  2020cites this paper
• Effect of the Hsp90 Inhibitor KW-2478 on HepG2 Cells.

  2020cites this paper
• Enhanced anti-hepatoma effect of a novel curcumin analog C086 via solid dispersion technology

  2020cites this paper
• Heat Shock Protein 90 and Reproduction in Female Animals: Ovary, Oocyte and Early Embryo

  2019cites this paper
• A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

  2019cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Disease-modifying therapies for tauopathies: agents in the pipeline

  2019cites this paper
• HSP90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application

  2019cites this paper
• Role of HSP90 Inhibitors in the Treatment of Cancer

  2019cites this paper
• Old and New Approaches to Target the Hsp90 Chaperone.

  2019cites this paper
• High expression of HSP90 is associated with poor prognosis in patients with colorectal cancer

  2019cites this paper
• Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy

  2019cites this paper
• The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor

  2019cites this paper
• Screening Technique for Heat Shock Protein 90 Inhibitors from Natural Products

  2019cites this paper
• CHARACTERIZATION OF HSP90 SUBPOPULATION CONFORMATIONS TARGETED BY INHIBITORS AND THE EFFECT OF PHOSPHORYLATION ON HSP90’S ASSOCIATION WITH CO-CHAPERONE AND CLIENT PROTEINS

  2019cites this paper
• Recent progresses on anti-aging compounds and their targets in Caenorhabditis elegans

  2019cites this paper
• Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain

  2018cites this paper
• PET imaging of Hsp90 expression in pancreatic cancer using a new 64Cu-labeled dimeric Sansalvamide A decapeptide

  2018cites this paper
• Heat Shock Protein 70 and Molecular Confession During Neurodegeneration

  2018cites this paper
• Chapter 2 Recent Advances in Tumor Targeting Approaches

  2018cites this paper
• DnaJ/Hsp40 Family and Parkinson's Disease

  2018cites this paper
• Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway

  2018cites this paper
• A high-content screen identifies HSP90 as a component of axon injury signaling

  2018cites this paper
• Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients

  2017cites this paper
• Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents.

  2017cites this paper
• 热休克蛋白90抑制剂17-AAG对HUT-102细胞株JAK3/STAT5信号通路的影响

  2017cites this paper
• A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

  2017cites this paper
• Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors.

  2017cites this paper
• Synthesis and Structure–Activity Relationships of Inhibitors That Target the C-Terminal MEEVD on Heat Shock Protein 90

  2017cites this paper
• Imatinib: Basic Results

  2017cites this paper
• New Generation Cancer Drug Studies: Hsp90 Inhibitors

  2016cites this paper
• Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.

  2016cites this paper
• Mechanism of Inhibition of Hsp90 Dimerization by Gyrase B Inhibitor Coumermycin A1 (C–A1) Revealed by Molecular Dynamics Simulations and Thermodynamic Calculations

  2016cites this paper
• Novel Hsp 90 Inhibitor , Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer

  2016influential citation
• Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery.

  2016cites this paper
• Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells

  2016cites this paper
• Novel molecular mechanisms involved in the pathogenesis of GH-secreting pituitary adenomas

  2016cites this paper
• Therapeutic strategies for the treatment of tauopathies: Hopes and challenges

  2016cites this paper
• Unfolding the Hsp90 Foldasome: Structure-Activity Relationship Studies on EGCG and Development of Isoform-Selective Inhibitors

  2016cites this paper
• CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells

  2016cites this paper
• Recent Advances in Tumor Targeting Approaches

  2015cites this paper
• The Role of Tumor Suppressor Co-Chaperone CHIP/STUB1 in ERBB2-Mediated Oncogenesis

  2015cites this paper
• 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition

  2015cites this paper
• Heat Shock Protein 90 Inhibitor (17-AAG) Induces Apoptosis and Decreases Cell Migration/Motility of Keloid Fibroblasts

  2015cites this paper
• Hsp 90 Inhibitors : What ’ s Taking So Long ?

  2015cites this paper
• Heat shock protein 90 inhibition by 17-DMAG attenuates abdominal aortic aneurysm formation in mice.

  2015cites this paper
• Low-dose HSP90 inhibitors DPB and AUY-922 repress apoptosis in HUVECs

  2015cites this paper
• Pharmacologic heat shock protein 70 induction confers cytoprotection against inflammation in gliovascular cells

  2015cites this paper
• 17-AAG enhances the cytotoxicity of flavopiridol in mantle cell lymphoma via autophagy suppression.

  2015influential citation
• A CHIPotle in physiology and disease.

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Designing Drugs Against Hsp90 for Cancer Therapy

  2014influential citation
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• The role of melatonin in pancreatic protection: could melatonin be used in the treatment of acute pancreatitis?

  2014cites this paper
• Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.

  2014cites this paper
• Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shape‐Based Similarity Screening

  2014cites this paper
• Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular carcinoma cells.

  2014cites this paper
• Targeting the LKB1 tumor suppressor.

  2014cites this paper
• Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling

  2014cites this paper
• Preclinical antitumor activity of SST0116CL1: A novel heat shock protein 90 inhibitor

  2014cites this paper
• Design, Synthesis and In vitro Anti-tumor Evaluation of Novel Acrylohydrazide Thioglycosides

  2014cites this paper
• Identification of two novel HSP90 proteins in Babesia orientalis: molecular characterization, and computational analyses of their structure, function, antigenicity and inhibitor interaction

  2014cites this paper
• Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide

  2014cites this paper
• Cancer Therapy : Preclinical NMS-E 973 , a Novel Synthetic Inhibitor of Hsp 90 with Activity against Multiple Models of Drug Resistance to Targeted Agents , Including Intracranial Metastases

  2013cites this paper
• Geldanamycin-Induced Phosphatidylserine Translocation in the Erythrocyte Membrane

  2013cites this paper
• NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

  2013cites this paper
• Including Intracranial Metastases against Multiple Models of Drug Resistance to Targeted Agents, NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity

  2013cites this paper
• Molecular chaperones as drug targets.

  2013cites this paper
• Opportunities and Challenges for Molecular Chaperone Modulation to Treat Protein-Conformational Brain Diseases

  2013influential citation
• B-Cell Antigen Receptor Signaling in Chronic Lymphocytic Leukemia: Therapeutic Targets and Translational Opportunities

  2013cites this paper
• Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis

  2013cites this paper
• Targeting heat shock protein 90 for malaria.

  2013cites this paper
• The role of amyloidogenic protein oligomerization in neurodegenerative disease

  2013cites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper